个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ ESCI

作者：
Wenxian Wang[1] * ; Bin Lian[2] * ; Chunwei Xu[3,4] * ; Qian Wang[5] * ; Ziming Li[6] ; Nan Zheng[7,8] ; Aijun Liu[9] ; Jinpu Yu[10] ; Wenzhao Zhong[11] ; Zhijie Wang[12] ; Yongchang Zhang[13] ; Jingjing Liu[14] ; Shirong Zhang[15] ; Xiuyu Cai[16] ; Anwen Liu[17] ; Wen Li[18] ; Lili Mao[2] ; Ping Zhan[4] ; Hongbing Liu[4] ; Tangfeng Lv[4] ; Liyun Miao[19] ; Lingfeng Min[20] ; Yu Chen[21] ; Jingping Yuan[22] ; Feng Wang[23] ; Zhansheng Jiang[24] ; Gen Lin[21] ; Long Huang[17] ; Xingxiang Pu[25] ; Rongbo Lin[21] ; Weifeng Liu[26] ; Chuangzhou Rao[27] ; Dongqing Lv[28] ; Zongyang Yu[29] ; Xiaoyan Li[30] ; Chuanhao Tang[31] ; Chengzhi Zhou[32] ; Junping Zhang[33] ; Junli Xue[34] ; Hui Guo[35] ; Qian Chu[36] ; Rui Meng[37] ; Xuewen Liu[38] ; Jingxun Wu[39] ; Rui Zhang[40] ; Jin Zhou[41] ; Zhengfei Zhu[42] ; Yongheng Li[43] ; Hong Qiu[36] ; Fan Xia[51] ; Yuanyuan Lu[44] ; Xiaofeng Chen[45] ; Jian Feng[46] ; Rui Ge[47] ; Enyong Dai[48] ; Yu Han[49] ; Weiwei Pan[50] ; Fei Pang[51] ; Xin Huang[51] ; Meizhen Hu[51] ; Qing Hao[51] ; Kai Wang[51] ; Fan Wu[52] ; Binbin Song[53] ; Bingwei Xu[54] ; Liping Wang[55] ; Youcai Zhu[56] ; Li Lin[31] ; Yanru Xie[57] ; Xinqing Lin[27] ; Jing Cai[17] ; Ling Xu[58] ; Jisheng Li[59] ; Xiaodong Jiao[60] ; Kainan Li[61] ; Jia Wei[62] ; Huijing Feng[33] ; Lin Wang[63] ; Yingying Du[64] ; Wang Yao[65] ; Xuefei Shi[66] ; Xiaomin Niu[6] ; Dongmei Yuan[4] ; Yanwen Yao[4] ; Jianhui Huang[57] ; Yue Feng[67] ; Yinbin Zhang[68] ; Pingli Sun[69] ; Hong Wang[70] ; Mingxiang Ye[4] ; Dong Wang[4] ; Zhaofeng Wang[4] ; Yue Hao[1] ; Zhen Wang[71] ; Bin Wan[72] ; Donglai Lv[73] ; Shengjie Yang[74] ; Jin Kang[11] ; Jiatao Zhang[11] ; Chao Zhang[11] ; Wenfeng Li[75] ; Jianfei Fu[76] ; Lizhi Wu[77] ; Shijie Lan[78] ; Juanjuan Ou[79] ; Lin Shi[80] ; Zhanqiang Zhai[56] ; Yina Wang[81] ; Bihui Li[82] ; Zhang Zhang[83] ; Ke Wang[84,85] ; Xuelei Ma[86] ; Zhongwu Li[87] ; Zhefeng Liu[70] ; Nong Yang[13] ; Lin Wu[25] ; Huijuan Wang[88] ; Gu Jin[89] ; Guansong Wang[90] ; Jiandong Wang[91] ; Hubing Shi[92] ; Meiyu Fang[1] ; Yong Fang[93] ; Yuan Li[94] ; Xiaojia Wang[1] ; Jing Chen[37] ; Yiping Zhang[1] ; Xixu Zhu[71] ; Yi Shen[95] ; Shenglin Ma[96] ; Biyun Wang[97] ; Yong Song[4] ; Zhengbo Song[1] ; Wenfeng Fang[98] ; Yuanzhi Lu[99] ; Lu Si[2] ;
机构： [1]Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, P.R. China [2]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute,Beijing 100142, P.R. China [3]Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China [4]Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, P.R. China [5]Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210029, P.R.China [6]Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, P.R. China [7]Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 200030, China [8]Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 200030, China [9]Senior Department of Pathology, the 7th Medical Center of PLA General Hospital, Beijing 100700, P.R. China [10]Department of Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China [11]Guangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, Guangdong 510080, P.R. China [12]State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China [13]Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, P.R. China [14]Department of Thoracic Cancer, Jilin Cancer Hospital, Jilin, Changchun 130012, P.R. China [15]Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Cancer Center, West Lake University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China [16]Department of VIP Inpatient, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,Guangzhou, Guangdong 510060, P.R. ChinaP.R. China [17]Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China [18]Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China [19]Department of Respiratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210008, P.R. China [20]Department of Respiratory Medicine, Clinical Medical School of Yangzhou University, Subei People’s Hospital of Jiangsu Province, Yangzhou, Jiangsu 225001, P.R. China [21]Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, Fujian 350014, P.R. China [22]Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China [23]Department of Internal Medicine, Cancer Center of PLA, Qinhuai Medical Area, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, P.R. China [24]Derpartment of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China [25]Department of Medical Oncology, Lung Cancer and Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha,Hunan 410013, P.R. China [26]Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Peking University, Beijing 100035, P.R. China [27]Department of Radiotherapy and Chemotherapy, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang 315010, P.R. China [28]Department of Pulmonary Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, Zhejiang 317000, P.R. China [29]Department of Respiratory Medicine, the 900th Hospital of the Joint Logistics Team (the Former Fuzhou General Hospital), Fujian Medical University, Fuzhou, Fujian 350025, P.R.China [30]Department of Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100700, P.R. China [31]Department of Medical Oncology, Peking University International Hospital, Beijing 102206, P.R. China [32]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510300, P.R. China [33]Department of Thoracic Oncology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, Shanxi 030032, P.R. China [34]Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200123, P.R. China [35]Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China [36]Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China [37]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China [38]Department of Oncology, the Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China [39]Department of Medical Oncology, the First Affiliated Hospital of Medicine, Xiamen University, Xiamen, Fujian 361003, P.R. China [40]Department of Medical Oncology, Cancer Hospital of China Medical University, Shenyang, Liaoning 110042, P.R. China [41]Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology, Chengdu,Sichuan 610041, P.R. China [42]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China [43]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute,Beijing 100142, P.R. China [44]State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an,Shaanxi 710032, P.R. China [45]Department of Oncology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu 210029, P.R. China [46]Department of Respiratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China [47]Department of General Surgery, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China [48]Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 13003, P.R. China [49]Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 1550081, P.R. China [50]Department of Cell Biology, College of Medicine, Jiaxing University, Jiaxing, Zhejiang 314001, P.R. China [51]Department of Medical, Shanghai OrigiMed Co., Ltd., Shanghai 201114, P.R. China [52]Department of Medical, Menarini Silicon Biosystems Spa, Shanghai 400000, P.R. China [53]Department of Medical Oncology, The Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China [54]Department of Biotherapy, Cancer Institute, First Affiliated Hospital of China Medical University, Shenyang 110001, P.R. China [55]Department of Oncology, Baotou Cancer Hospital, Baotou, Inner Mongolia 014000, P.R. China [56]Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China [57]Department of Oncology, Lishui Municipal Central Hospital, Lishui, Zhejiang 323000, P.R. China [58]Department of Interventional Pulmonary Diseases, Anhui Chest Hospital, Hefei, Anhui 230011, P.R. China [59]Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinnan, Shangdong 250012, P.R. China [60]Department of Medical Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai 200070, P.R. China [61]Department of Oncology, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250031, P.R. China [62]Department of the Comprehensive Cancer Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210008, P.R. China [63]Department of Pathology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, Shanxi 030032, P.R. China [64]Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China [65]Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510060, P.R. China [66]Department of Respiratory Medicine, Huzhou Hospital, Zhejiang University School of Medicine, Huzhou, Zhejiang 313000, P.R. China [67]Department of Gynecologic Radiation Oncology, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, P.R. China [68]Department of Oncology, the Second Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an, Shaanxi 710004, P.R. China [69]Department of Pathology, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China [70]Senior Department of Oncology, The 5th Medical Center of PLA General Hospital, Beijing 100071, P.R. China [71]Department of Radiation Oncology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, P.R. China [72]Department of Respiratory Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu 210002, P.R. China [73]Department of Clinical Oncology, The 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei, Anhui 230031, P.R. China [74]Department of Thoracic Surgery, Chuxiong Yi Autonomous Prefecture People’s Hospital, Chuxiong, Yunnan 675000, P.R. China [75]Department of Radiation Oncology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang 325000, China [76]Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang 321000, P.R. China [77]Department of Microsurgery, Taizhou Hospital Affiliated to Wenzhou Medical University, Taizhou, Zhejiang 317000, China [78]Department of Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China [79]Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, P.R. China [80]Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China [81]Department of Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China [82]Department of Oncology, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541199, P.R. China [83]International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, Guangzhou, Guangdong 510632, P.R. China [84]National Health Commission (NHC) Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China [85]Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu 210000, People’s Republic of China [86]Department of Biotherapy, State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China [87]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing 100142, P.R. China [88]Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450000, P.R. China [89]Department of Bone and Soft-tissue Surgery, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, P.R. China [90]Institute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China [91]Department of Pathology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, P.R. China [92]Frontier Science Center for Disease Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China [93]Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China [94]Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China [95]Department of Thoracic Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, P.R. China [96]Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Cancer Center,Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China [97]Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University,Shanghai 200032, P.R. China [98]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,Guangzhou, Guangdong 510060, P.R. China [99]Department of Clinical Pathology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, P.R. China
出处：
DOI： 10.1016/j.xinn.2024.100661
ISSN：

摘要：
The BRAF gene is an important signaling molecule in human cells that is involved in the regulation of cell growth, differentiation, and survival. When the BRAF gene mutates, it can lead to abnormal activation of the signaling pathway, which promotes cell proliferation, inhibits cell apoptosis, and ultimately contributes to the occurrence and development of cancer. BRAF mutations are widely present in various cancers, including malignant melanoma, thyroid cancer, colorectal cancer, non-small cell lung cancer, and hairy cell leukemia, among others. BRAF is an important target for the treatment of various solid tumors, and targeted combination therapies, represented by BRAF inhibitors, have become one of the main treatment modalities for a variety of BRAF-mutation-positive solid tumors. Dabrafenib plus trametinib, as the first tumor-agnostic therapy, has been approved by the US Food and Drug Administration for the treatment of adult and pediatric patients aged 6 years and older harboring a BRAF V600E mutation with unresectable or metastatic solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. This is also the first time a BRAF/MEK inhibitor combination has been approved for use in pediatric patients. As research into the diagnosis and treatment of BRAF mutations advances, standardizing the detection of BRAF mutations and the clinical application of BRAF inhibitors becomes increasingly important. Therefore, we have established a universal and systematic strategy for diagnosing and treating solid tumors with BRAF mutations. In this expert consensus, we (1) summarize the epidemiology and clinical characteristics of BRAF mutations in different solid tumors, (2) provide recommendations for the selection of genetic testing methods and platforms, and (3) establish a universal strategy for the diagnosis and treatment of patients with solid tumors harboring BRAF mutations.© 2024 The Author(s).

基金：
This work was supported by the Natural Science Foundation of China (grant number 82002456), China Postdoctoral Science Foundation (grant number 2022M723207), the Medical Scientific Research Foundation of Zhejiang Province, China (grant number 2023KY666), Zhejiang Traditional Chinese Medicine Science Fund Project (grant number 2024ZL372), Qiantang Cross Fund Project (grant number 2023-16), National Natural Science Foundation of China of Zhejiang Cancer Hospital Cultivation Project (grant number PY2023006), the Medical Scientific Research Foundation of Zhejiang Province, China (grant number 2024KY812), and the Natural Science Foundation of Zhejiang Province (grant number LQ24H160036), Beijing Health Technologies Promotion Program [grant number BHTPP2022041], Peking University Clinical Scientist Training Program and the Fundamental Research Funds for the Central Universities [grant number BMU2024PYJH010], Science Foundation of Peking University Cancer Hospital [grant number PY202333], the Beijing Natural Science Foundation [grant number 7232248] and Beijing Hospitals Authority Youth Programme [grant number QML20231902].
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
JCR分区：
出版当年[2023]版：
Q1 MULTIDISCIPLINARY SCIENCES
最新[2023]版：
Q1 MULTIDISCIPLINARY SCIENCES

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, P.R. China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Wenxian Wang,Bin Lian,Chunwei Xu,et al.Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations[J].INNOVATION.2024,5(6):doi:10.1016/j.xinn.2024.100661.
APA：
Wenxian Wang,Bin Lian,Chunwei Xu,Qian Wang,Ziming Li...&Lu Si.(2024).Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations.INNOVATION,5,(6)
MLA：
Wenxian Wang,et al."Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations".INNOVATION 5..6(2024)

资源点击量：84979 今日访问量：0 总访问量：692 更新日期：2025-02-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西山区金碧路157号